The importance of developing therapies targeting the biological spectrum of metastatic disease. Author Andries Zijlstra, Ariana Von Lersner, Dihua Yu, Lucia Borrello, Madeleine Oudin, Yibin Kang, Erik Sahai, Barbara Fingleton, Ulrike Stein, Thomas Cox, John Price, Yasumasa Kato, Alana Welm, Julio Aguirre-Ghiso, Board Members of the Metastasis Research Society Publication Year 2019 Type Journal Article Abstract Great progress has been made in cancer therapeutics. However, metastasis remains the predominant cause of death from cancer. Importantly, metastasis can manifest many years after initial treatment of the primary cancer. This is because cancer cells can remain dormant before forming symptomatic metastasis. An important question is whether metastasis research should focus on the early treatment of metastases, before they are clinically evident ("overt"), or on developing treatments to stop overt metastasis (stage IV cancer). In this commentary we want to clarify why it is important that all avenues of treatment for stage IV patients are developed. Indeed, future treatments are expected to go beyond the mere shrinkage of overt metastases and will include strategies that prevent disseminated tumor cells from emerging from dormancy. Keywords Animals, Humans, Neoplasm Metastasis, Drug Development Journal Clin Exp Metastasis Volume 36 Issue 4 Pages 305-309 Date Published 2019 Aug ISSN Number 1573-7276 DOI 10.1007/s10585-019-09972-3 Alternate Journal Clin Exp Metastasis PMCID PMC8794535 PMID 31102066 PubMedPubMed CentralGoogle ScholarBibTeXEndNote X3 XML